Max Hodak’s Science Corp. Is Preparing to Place Its First Sensor in a Human Brain

Why It Matters

The trial marks the first human test of a bio‑hybrid BCI that could overcome the tissue damage associated with traditional metal probes, potentially accelerating commercial neuroprosthetics and expanding therapeutic options for chronic brain conditions.

Key Takeaways

• Science Corp raised $230M Series C, valuing it at $1.5B.
• Yale neurobiologist Murat Günel joins as scientific adviser for trials.
• First human trial will test sensor without neurons on stroke surgery patients.
• Device uses 520 electrodes, sits on cortex, avoids FDA filing claim.
• Bio‑hybrid approach aims to treat blindness, Parkinson’s, and seizures.

Pulse Analysis

Neurotechnology firms have long chased the promise of seamless brain‑computer interfaces, but most commercial efforts still rely on rigid metal electrodes that can scar tissue and degrade signal quality over time. Science Corp, backed by a $230 million Series C raise, is betting on a different paradigm: a bio‑hybrid sensor that couples thin‑film electronics with lab‑grown neurons. By positioning the device on the surface of the brain rather than penetrating it, the startup hopes to reduce inflammatory responses while still capturing high‑resolution neural data. This approach aligns with a broader industry shift toward softer, more biocompatible interfaces, as seen in recent academic prototypes and early‑stage ventures.

The upcoming human trial, slated for 2027, will initially evaluate the sensor without its neuronal component, leveraging patients who already require craniotomies for conditions such as stroke‑induced swelling. This patient‑centric recruitment strategy sidesteps the need for a full FDA Investigational Device Exemption, as the company argues the implant poses minimal risk. The device’s 520 recording electrodes, packed into a pea‑sized footprint, aim to deliver dense electrophysiological mapping while remaining removable. If safety and signal fidelity are confirmed, the next phase will integrate cultured neurons that can be optogenetically stimulated, potentially creating a two‑way communication bridge between brain tissue and external processors.

Commercially, a successful bio‑hybrid BCI could unlock new revenue streams beyond the niche markets of paralysis or ALS, extending into ophthalmology, movement disorders, and seizure monitoring. The ability to deliver targeted electrical stimulation while simultaneously recording activity may enable disease‑modifying therapies for Parkinson’s and other neurodegenerative conditions. Moreover, the technology could attract strategic partnerships with pharmaceutical firms seeking neuromodulation platforms, as well as defense and consumer sectors interested in augmented cognition. However, regulatory clarity and scalable manufacturing of viable neuron cultures remain critical hurdles that will shape the timeline for market entry.